[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598128":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":28,"locations":34,"responsibleParty":204,"collaborators":11,"id":206,"slug":207,"hasResults":208,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":11,"eligibilityCriteria":212,"healthyVolunteers":208,"sex":213,"minAge":214,"maxAge":215,"enrollmentInfo":216,"targetDuration":11,"studyType":219,"phases":220,"briefSummary":222,"conditions":223,"keywords":11,"overallStatus":37,"whyStopped":11,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":234},{"fullName":5,"class":6},"Zenas BioPharma (USA), LLC","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Orelabrutinib Group","EXPERIMENTAL",null,[13],"Drug: Orelabrutinib",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo Group","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Orelabrutinib","Orally",[9],{"type":21,"name":26,"description":23,"armGroupLabels":27,"otherNames":11},"Placebo",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},"Patient and Medical Information","CONTACT","833-269-4696","clinicaltrialsinfo@zenasbio.com",[35,43,53,63,73,82,92,102,112,122,132,142,151,161,173,185,195],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":11,"geoPoint":11,"contacts":11},"Arizona Neuroscience Research, LLC","RECRUITING","Pheonix","Arizona","85032","United States","US",{"facility":44,"status":37,"city":45,"state":39,"zip":46,"country":41,"countryCode":42,"cosmosGeoPoint":47,"geoPoint":52,"contacts":11},"Perseverance Research Center","Scottsdale","85253",{"type":48,"coordinates":49},"Point",[50,51],-111.89903,33.50921,{"lat":51,"lon":50},{"facility":54,"status":37,"city":55,"state":56,"zip":57,"country":41,"countryCode":42,"cosmosGeoPoint":58,"geoPoint":62,"contacts":11},"Regina Berkovich MD, PhD Inc.","West Hollywood","California","90048",{"type":48,"coordinates":59},[60,61],-118.36174,34.09001,{"lat":61,"lon":60},{"facility":64,"status":37,"city":65,"state":66,"zip":67,"country":41,"countryCode":42,"cosmosGeoPoint":68,"geoPoint":72,"contacts":11},"Nova Clinical Research, LLC","Bradenton","Florida","34209",{"type":48,"coordinates":69},[70,71],-82.57482,27.49893,{"lat":71,"lon":70},{"facility":74,"status":37,"city":75,"state":66,"zip":76,"country":41,"countryCode":42,"cosmosGeoPoint":77,"geoPoint":81,"contacts":11},"Neurology Associates, PA","Maitland","32751",{"type":48,"coordinates":78},[79,80],-81.36312,28.62778,{"lat":80,"lon":79},{"facility":83,"status":37,"city":84,"state":85,"zip":86,"country":41,"countryCode":42,"cosmosGeoPoint":87,"geoPoint":91,"contacts":11},"Washington University School of Medicine","St Louis","Missouri","63110",{"type":48,"coordinates":88},[89,90],-90.19789,38.62727,{"lat":90,"lon":89},{"facility":93,"status":37,"city":94,"state":95,"zip":96,"country":41,"countryCode":42,"cosmosGeoPoint":97,"geoPoint":101,"contacts":11},"Velocity Clinical Research, Raleigh Neurology","Raleigh","North Carolina","27607",{"type":48,"coordinates":98},[99,100],-78.63861,35.7721,{"lat":100,"lon":99},{"facility":103,"status":37,"city":104,"state":105,"zip":106,"country":41,"countryCode":42,"cosmosGeoPoint":107,"geoPoint":111,"contacts":11},"The Boster Center for Multiple Sclerosis","Columbus","Ohio","43235",{"type":48,"coordinates":108},[109,110],-82.99879,39.96118,{"lat":110,"lon":109},{"facility":113,"status":37,"city":114,"state":115,"zip":116,"country":41,"countryCode":42,"cosmosGeoPoint":117,"geoPoint":121,"contacts":11},"Premier Neurology","Greenville","South Carolina","29605",{"type":48,"coordinates":118},[119,120],-82.39401,34.85262,{"lat":120,"lon":119},{"facility":123,"status":37,"city":124,"state":125,"zip":126,"country":41,"countryCode":42,"cosmosGeoPoint":127,"geoPoint":131,"contacts":11},"Neurology Clinic, P.C.","Cordova","Tennessee","38018",{"type":48,"coordinates":128},[129,130],-89.7762,35.15565,{"lat":130,"lon":129},{"facility":133,"status":37,"city":134,"state":135,"zip":136,"country":41,"countryCode":42,"cosmosGeoPoint":137,"geoPoint":141,"contacts":11},"Lone Star Neurology","San Antonio","Texas","78258",{"type":48,"coordinates":138},[139,140],-98.49363,29.42412,{"lat":140,"lon":139},{"facility":143,"status":37,"city":144,"state":135,"zip":145,"country":41,"countryCode":42,"cosmosGeoPoint":146,"geoPoint":150,"contacts":11},"Texas Institute for Neurological Disorders","Sherman","75092",{"type":48,"coordinates":147},[148,149],-96.60888,33.63566,{"lat":149,"lon":148},{"facility":152,"status":37,"city":153,"state":11,"zip":154,"country":155,"countryCode":11,"cosmosGeoPoint":156,"geoPoint":160,"contacts":11},"NEUROHK, s.r.o.","Choceň","56501","Czechia",{"type":48,"coordinates":157},[158,159],16.22303,50.00161,{"lat":159,"lon":158},{"facility":162,"status":37,"city":163,"state":164,"zip":165,"country":166,"countryCode":167,"cosmosGeoPoint":168,"geoPoint":172,"contacts":11},"Neuro Centrum Science Gmbh Albert-Schwitzer","Erbach im Odenwald","Hesse","64711","Germany","DE",{"type":48,"coordinates":169},[170,171],8.99402,49.66148,{"lat":171,"lon":170},{"facility":174,"status":37,"city":175,"state":176,"zip":177,"country":178,"countryCode":179,"cosmosGeoPoint":180,"geoPoint":184,"contacts":11},"NZOZ Novo Med","Katowice","Silesian Voivodeship","40-584","Poland","PL",{"type":48,"coordinates":181},[182,183],19.02173,50.2597,{"lat":183,"lon":182},{"facility":186,"status":37,"city":187,"state":188,"zip":189,"country":178,"countryCode":179,"cosmosGeoPoint":190,"geoPoint":194,"contacts":11},"Nzoz Neuro-Kard Ilkowski I Partnerzy Spolka Partnerska Lekarzy","Poznan","Wielkopolska","61-853",{"type":48,"coordinates":191},[192,193],16.92993,52.40692,{"lat":193,"lon":192},{"facility":196,"status":37,"city":197,"state":11,"zip":198,"country":178,"countryCode":179,"cosmosGeoPoint":199,"geoPoint":203,"contacts":11},"NZOZ Neuromed M. i M. Nastaj Sp.P","Lublin","20-064",{"type":48,"coordinates":200},[201,202],22.57009,51.25058,{"lat":202,"lon":201},{"type":205,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100598128","phase-3-a-study-of-orelabrutinib-in-patients-with-primary-progressive-multiple-sclerosis-100598128",false,"NCT07067463","A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis","A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis","Inclusion Criteria:\n\n* 18 to 60 years of age, inclusive\n* Diagnosed with Primary Progressive MS (PPMS) according to 2017 McDonald criteria\n* Participant must have documented evidence of disability progression observed during the 24 months before screening.\n* Expanded disability status scale (EDSS) score between 3.0 to 6.5 points, inclusive, at Screening.\n\nExclusion Criteria:\n\n* Diagnosed with relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS)\n* Immunologic disorder other than MS or any other conditions requiring oral, intravenous (IV), intramuscular, or intra-articular corticosteroid therapy.\n* History or current diagnosis of other neurological disorders that may mimic MS\n* History of any other significant active medical condition\n* History of suicidal behavior within 6 months prior to Screening\n* Any prior history of malignancy if no recurrence within 5 years\n* Patients on anticoagulation, or antiplatelet therapy will be excluded\n* Patients took strong\u002Fmoderate CYP3A inhibitors or strong\u002Fmoderate CYP3A inducerswithin 14 days\n* Clinically significant laboratory abnormalities at Screening.\n* Any allergy, contraindication, or inability to tolerate orelabrutinib or any of the excipients in the study intervention\n* Vaccination with live or live-attenuated virus vaccine within 1 month prior to Screening\n* History of alcohol abuse or alcohol use disorder or other drug abuse within 12 months prior to screening.","ALL","18 Years","60 Years",{"count":217,"type":218},705,"ESTIMATED","INTERVENTIONAL",[221],"PHASE3","Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS. Patients will be treated for approximately 30 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 705 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.",[224],"Multiple Sclerosis (MS) Primary Progressive","2026-06-26",{"date":227,"type":228},"2026-06-29","ACTUAL",{"date":230,"type":228},"2026-03-23",{"date":232,"type":218},"2030-07",{"name":5,"class":6},17]